Educational only, not medical advice: Most peptides on this chart are research chemicals that are not FDA-approved. The cycle lengths below are what people commonly report or what labels and trials used, not a personal plan. This page does not cover doses; see the Peptide Dosage Guide for those. Talk to a qualified healthcare provider before starting, stopping or changing anything.
Short Answer
Most research peptides are run in cycles of a few weeks to a few months, followed by a break. Healing peptides like BPC-157 and TB-500 are commonly run 8 to 12 weeks; growth hormone peptides like CJC-1295 and Ipamorelin are often run 12 to 16 weeks with 4 to 6 weeks off. These numbers come from community practice, not clinical trials. FDA-approved drugs like semaglutide and tirzepatide are different: they are taken continuously under a prescriber, and stopping them is linked to weight regain.
Peptide Cycle Chart
The "Basis" column tells you where each cycle length comes from, so you can see how much evidence sits behind it.
| Peptide | Typical cycle | Basis |
|---|---|---|
| BPC-157 | 8 to 12 weeks on, 4 off | Community |
| TB-500 | 8 to 12 weeks | Community |
| CJC-1295 (no DAC) | 12 to 16 weeks on, 4 to 6 off | Community |
| CJC-1295 (with DAC) | 12 to 16 weeks on, 4 to 6 off | Community |
| Ipamorelin | 12 to 16 weeks on, 4 to 6 off | Community |
| GHK-Cu (injected) | Often 8 to 12 weeks | Community |
| KPV (oral) | Varies | Community |
| Sermorelin | Varies | Community |
| IGF-1 LR3 | 4 to 6 weeks | Community |
| MOTS-c | Short courses | Community |
| Semax | Short courses | Community |
| Selank | In cycles | Community |
| Epithalon | Short courses, 1 to 2 times a year | Community |
| DSIP | Short-term | Community |
| Tesamorelin | Prescriber-led | FDA label |
| Semaglutide | Ongoing, under a prescriber | FDA label |
| Tirzepatide | Ongoing, under a prescriber | FDA label |
| Retatrutide | Continuous in clinical trials (investigational) | Trial |
Community means the length comes from user and vendor protocols, not a study. FDA label means it follows an approved drug's prescribing information. Trial means it reflects how a drug was given in clinical trials.
Why People Cycle Peptides
The usual reason is the idea that receptors become less responsive with constant stimulation, so a break "resets" the response. For most peptides this has not been tested in people. The best human evidence comes from the growth hormone releasing peptides. In a study of 12 healthy older adults given hexarelin, a GH releasing peptide, by injection twice daily for 16 weeks, the growth hormone response fell significantly by week 4 and week 16, then returned to baseline 4 weeks after stopping. Hexarelin is a relative of ipamorelin, not the same molecule, so this supports the logic of breaks for GH peptides without proving any specific schedule.
Other common reasons to cycle are simpler: to see whether the benefit holds after stopping, to limit long-term exposure to compounds with little long-term safety data, and to get bloodwork without the peptide on board.
Peptides That Are Taken Continuously
GLP-1 drugs are the main exception. In the STEP 4 trial, 803 adults who had already lost weight on semaglutide for 20 weeks were randomly assigned to continue it or switch to placebo for 48 more weeks. Those who continued kept losing weight, while those switched to placebo regained weight. That is why the labels for semaglutide and tirzepatide describe ongoing treatment under a prescriber rather than on and off cycles, and why retatrutide was given continuously in its trials.
Special Cases
GHK-Cu and copper
GHK-Cu is a copper peptide, so long runs add copper. The adult Tolerable Upper Intake Level for copper is 10 mg a day from all sources, set to protect the liver, and it was set for copper you eat, not inject. Long-term injected GHK-Cu has not been studied. Anyone with Wilson's disease or another copper disorder should avoid it. See GHK-Cu for more.
Short-course peptides
Epithalon, Semax, MOTS-c and DSIP are usually described in short courses rather than long cycles, often repeated once or twice a year. Human data on all four is limited, so the course lengths are conventions, not tested schedules.
What to Check Between Cycles
A break is a good time for bloodwork, since it shows where you are without the peptide on board. Many people repeat the same panel at baseline, near the end of a cycle and during the break. Common markers include a CMP for liver and kidney function, a CBC, fasting glucose and HbA1c, IGF-1 for growth hormone peptides, and copper markers for long GHK-Cu runs. See the Peptide Bloodwork Guide, track your results with Lab Analysis, and log each cycle with How to Track Your Peptide Cycles.
Related Reading
For doses, mixing and schedules, see the Peptide Dosage Guide. To build a stack around your goals, try the Protocol Builder. For more real questions, browse Peptide Questions Answered.
Frequently Asked Questions
How long should you cycle peptides?
Most research peptides are run for a few weeks to a few months, then paused. Healing peptides like BPC-157 and TB-500 are commonly run 8 to 12 weeks, and growth hormone peptides like CJC-1295 and Ipamorelin are often run 12 to 16 weeks with 4 to 6 weeks off. These lengths come from community practice, not clinical trials.
Why do people take breaks from peptides?
The main idea is that receptors may become less responsive with constant use. In a 16-week human study of hexarelin, a growth hormone releasing peptide, the growth hormone response dropped during treatment and returned to baseline 4 weeks after stopping. Breaks also allow clean bloodwork and limit long-term exposure to compounds with little safety data.
Do you need to cycle semaglutide or tirzepatide?
No. Semaglutide and tirzepatide are FDA-approved and are taken continuously under a prescriber. In the STEP 4 trial, people who stopped semaglutide regained weight while those who continued kept losing weight.
Can you take BPC-157 year round?
There is no human research on taking BPC-157 long term, so nobody knows. Community protocols commonly run it 8 to 12 weeks with about 4 weeks off. Talk to a healthcare provider before using it at all.
What bloodwork should you get between peptide cycles?
Common markers include a CMP for liver and kidney function, a CBC, fasting glucose and HbA1c, IGF-1 for growth hormone peptides, and copper markers for long GHK-Cu use. Many people check at baseline, near the end of a cycle and during the break.